3Wile DJ,Toth C.Association of mefformin, elevated homocysteine, and methyhnalonic acid levels and clinically worsened diabetic peripheral neuropathy[ J ] .Diabetes Care, 2010,33 ( 1 ) : 156-161.
4Boulton AJ.Whither clinical research in diabetic sensorimotor peripheral neuropathy? Problems of end point selection for clinical trials[ J ] .Diabetes Care, 2007,30 ( 10 ) : 2752-2753.
5Boulton AJ, Vinik AI, Arezzo JC, et al.Diabetic neuropathies: a statement by the American Diabetes Association[ J ] .Diabetes Care, 2005,28 ( 4 ) : 956-962.
6Moghtaderi A, Bakhshipour A, Rashidi H.Validation of Michigan neuropathy screening instrument for diabetic peripheral neuropathy[ J ] .Clin Neurol Neurosurg, 2006,108 ( 5 ): 477-481.
7Casellini CM, Barlow PM, Rice AL, et al.A 6-month, randomized, double-masked, placebo-controlled study evaluating the effects of the protein kinase C-beta inhibitor ruboxistaurin on skin microvascular blood flow and other measures of diabetic peripheral neuropathy[ J ] .Diabetes Care, 2007,30 ( 4 ) : 896-902.
8Erbas T, Ertas M, Yucel A, et al.Prevalence of peripheral neuropathy and painful peripheral neuropathy in Turkish diabetic patients[ J ] .J Clin Neurophysiol, 2011,28 ( 1 ) : 51-55.
